Published in Interact Cardiovasc Thorac Surg on October 09, 2012
Vascular wall extracellular matrix proteins and vascular diseases. Biochim Biophys Acta (2014) 0.99
COL3A1 and SNAP91: novel glioblastoma markers with diagnostic and prognostic value. Oncotarget (2016) 0.79
Comparison of different statistical approaches for urinary peptide biomarker detection in the context of coronary artery disease. BMC Bioinformatics (2016) 0.75
Aortic Wall Extracellular Matrix Proteins Correlate with Syntax Score in Patients Undergoing Coronary Artery Bypass Surgery. Open Cardiovasc Med J (2016) 0.75
High-density lipoprotein: a novel target for antirestenosis therapy. Clin Transl Sci (2014) 0.75
Prediction of acute coronary syndromes by urinary proteome analysis. PLoS One (2017) 0.75
Identification of a molecular signaling gene-gene regulatory network between GWAS susceptibility genes ADTRP and MIA3/TANGO1 for coronary artery disease. Biochim Biophys Acta (2017) 0.75
Pathophysiology of coronary artery disease. Circulation (2005) 6.65
Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation (1994) 6.03
From vulnerable plaque to vulnerable patient--Part III: Executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report. Am J Cardiol (2006) 3.82
Role of smooth muscle cells in the initiation and early progression of atherosclerosis. Arterioscler Thromb Vasc Biol (2008) 3.79
Atherothrombosis and high-risk plaque: part I: evolving concepts. J Am Coll Cardiol (2005) 3.34
Cardiac interstitium in health and disease: the fibrillar collagen network. J Am Coll Cardiol (1989) 2.95
Interstitial collagenase (MMP-1) expression in human carotid atherosclerosis. Circulation (1995) 1.73
Novel biomarkers in cardiovascular disease: update 2010. Am Heart J (2010) 1.43
Structural studies of matrix metalloproteinases. J Mol Med (Berl) (2000) 1.26
Vulnerable atherosclerotic plaque metalloproteinases and foam cell phenotypes. Thromb Haemost (2009) 1.24
The autoimmune origin of atherosclerosis. Atherosclerosis (2008) 1.17
Cytokine profiles and T cell function in acute coronary syndromes. Atherosclerosis (2006) 0.93
Basic fibroblast growth factor in the extracellular matrix suppresses collagen synthesis and type III procollagen mRNA levels in arterial smooth muscle cell cultures. Arterioscler Thromb (1993) 0.89
A 2-h diagnostic protocol to assess patients with chest pain symptoms in the Asia-Pacific region (ASPECT): a prospective observational validation study. Lancet (2011) 5.61
Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell Res (2010) 4.06
N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. J Am Coll Cardiol (2009) 4.00
2-Hour accelerated diagnostic protocol to assess patients with chest pain symptoms using contemporary troponins as the only biomarker: the ADAPT trial. J Am Coll Cardiol (2012) 3.15
Mesenchymal stem cell secretes microparticles enriched in pre-microRNAs. Nucleic Acids Res (2009) 2.66
Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction. J Am Coll Cardiol (2007) 2.60
Integrated hemodynamic, hormonal, and renal actions of urocortin 2 in normal and paced sheep: beneficial effects in heart failure. Circulation (2005) 2.34
Validation of high-sensitivity troponin I in a 2-hour diagnostic strategy to assess 30-day outcomes in emergency department patients with possible acute coronary syndrome. J Am Coll Cardiol (2013) 2.28
B-type natriuretic peptide signal peptide circulates in human blood: evaluation as a potential biomarker of cardiac ischemia. Circulation (2010) 2.26
A randomized trial of the aldosterone-receptor antagonist eplerenone in asymptomatic moderate-severe aortic stenosis. Am Heart J (2008) 2.04
Reduction of myocardial infarct size by human mesenchymal stem cell conditioned medium. Stem Cell Res (2008) 1.97
Cardiac chymase converts rat proAngiotensin-12 (PA12) to angiotensin II: effects of PA12 upon cardiac haemodynamics. Cardiovasc Res (2009) 1.83
Brain natriuretic peptide and n-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol (2003) 1.80
Plasma aldosterone levels during hospitalization are predictive of survival post-myocardial infarction. Eur Heart J (2008) 1.58
Angiotensin-converting enzyme gene polymorphism interacts with left ventricular ejection fraction and brain natriuretic peptide levels to predict mortality after myocardial infarction. J Am Coll Cardiol (2003) 1.55
Serial Doppler echocardiography and tissue Doppler imaging in the detection of elevated directly measured left atrial pressure in ambulant subjects with chronic heart failure. JACC Cardiovasc Imaging (2011) 1.54
Early dynamic change in high-sensitivity cardiac troponin T in the investigation of acute myocardial infarction. Clin Chem (2011) 1.54
Evaluation of AMPD1 C34T genotype as a predictor of mortality in heart failure and post-myocardial infarction patients. Am Heart J (2006) 1.52
Elucidating the secretion proteome of human embryonic stem cell-derived mesenchymal stem cells. Mol Cell Proteomics (2007) 1.51
Fibrates may cause an abnormal urinary betaine loss which is associated with elevations in plasma homocysteine. Cardiovasc Drugs Ther (2009) 1.49
Off-pump coronary bypass grafting is safe and efficient in patients with left main disease and higher EuroScore. Eur J Cardiothorac Surg (2009) 1.49
ST2 has diagnostic and prognostic utility for all-cause mortality and heart failure in patients presenting to the emergency department with chest pain. J Card Fail (2012) 1.47
High-sensitivity troponin T for early rule-out of myocardial infarction in recent onset chest pain. Emerg Med J (2011) 1.44
Direct left atrial pressure monitoring in ambulatory heart failure patients: initial experience with a new permanent implantable device. Circulation (2007) 1.43
Biology of the natriuretic peptides. Am J Cardiol (2008) 1.41
N-terminal pro-C-type natriuretic peptide, but not C-type natriuretic peptide, is greatly elevated in the fetal circulation. Clin Sci (Lond) (2004) 1.41
Plasma B-type natriuretic peptide levels in systolic heart failure: importance of left ventricular diastolic function and right ventricular systolic function. J Am Coll Cardiol (2004) 1.41
Increased plasma natriuretic peptide levels reflect symptom onset in aortic stenosis. Circulation (2003) 1.38
New biomarkers in heart failure: applications in diagnosis, prognosis and guidance of therapy. Rev Esp Cardiol (2010) 1.38
Coenzyme Q10: an independent predictor of mortality in chronic heart failure. J Am Coll Cardiol (2008) 1.35
Enabling a robust scalable manufacturing process for therapeutic exosomes through oncogenic immortalization of human ESC-derived MSCs. J Transl Med (2011) 1.29
Amino-terminal pro-brain natriuretic Peptide, renal function, and outcomes in acute heart failure: redefining the cardiorenal interaction? J Am Coll Cardiol (2006) 1.25
A common variant at chromosome 9P21.3 is associated with age of onset of coronary disease but not subsequent mortality. Circ Cardiovasc Genet (2010) 1.21
Relationship of serum sodium concentration to mortality in a wide spectrum of heart failure patients with preserved and with reduced ejection fraction: an individual patient data meta-analysis(†): Meta-Analysis Global Group in Chronic heart failure (MAGGIC). Eur J Heart Fail (2012) 1.21
Plasma natriuretic peptide levels increase with symptoms and severity of mitral regurgitation. J Am Coll Cardiol (2003) 1.20
Circulating microRNAs as candidate markers to distinguish heart failure in breathless patients. Eur J Heart Fail (2013) 1.20
Contractile and vasorelaxant effects of hydrogen sulfide and its biosynthesis in the human internal mammary artery. J Pharmacol Exp Ther (2007) 1.20
Genomic selection of reference genes for real-time PCR in human myocardium. BMC Med Genomics (2008) 1.19
Association of genetic variation in the natriuretic peptide system with cardiovascular outcomes. J Mol Cell Cardiol (2011) 1.17
Derivation and characterization of human fetal MSCs: an alternative cell source for large-scale production of cardioprotective microparticles. J Mol Cell Cardiol (2010) 1.13
A validated clinical and biochemical score for the diagnosis of acute heart failure: the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Acute Heart Failure Score. Am Heart J (2006) 1.11
Cardiac natriuretic peptides for cardiac health. Clin Sci (Lond) (2005) 1.06
Npr1-regulated gene pathways contributing to cardiac hypertrophy and fibrosis. J Mol Endocrinol (2007) 1.06
Severe obstructive sleep apnea and outcomes following myocardial infarction. J Clin Sleep Med (2011) 1.06
The neuro-cardio-endocrine response to acute subarachnoid haemorrhage. Clin Endocrinol (Oxf) (2002) 1.04
Association between the chromosome 9p21 locus and angiographic coronary artery disease burden: a collaborative meta-analysis. J Am Coll Cardiol (2013) 1.02
Transforming growth factor-beta blockade down-regulates the renin-angiotensin system and modifies cardiac remodeling after myocardial infarction. Endocrinology (2008) 1.01
Ascorbic acid improves embryonic cardiomyoblast cell survival and promotes vascularization in potential myocardial grafts in vivo. Tissue Eng Part A (2010) 0.99
B-type natriuretic peptide and long-term survival in patients with stable coronary artery disease. Am J Cardiol (2005) 0.99
Urocortin 2 infusion in healthy humans: hemodynamic, neurohormonal, and renal responses. J Am Coll Cardiol (2007) 0.98
Usefulness of serial measurement of N-terminal pro-brain natriuretic peptide plasma levels in asymptomatic patients with aortic stenosis to predict symptomatic deterioration. Am J Cardiol (2005) 0.98
Effect of beta blockade (carvedilol or metoprolol) on activation of the renin-angiotensin-aldosterone system and natriuretic peptides in chronic heart failure. Am J Cardiol (2003) 0.98
Resistin worsens cardiac ischaemia-reperfusion injury. Biochem Biophys Res Commun (2006) 0.97
Regional release and clearance of C-type natriuretic peptides in the human circulation and relation to cardiac function. Hypertension (2009) 0.97
Urocortin 3: haemodynamic, hormonal, and renal effects in experimental heart failure. Eur Heart J (2006) 0.97
Plasma lipids and betaine are related in an acute coronary syndrome cohort. PLoS One (2011) 0.97
Beneficial hemodynamic, endocrine, and renal effects of urocortin in experimental heart failure: comparison with normal sheep. J Am Coll Cardiol (2002) 0.96
Four-day urocortin-I administration has sustained beneficial haemodynamic, hormonal, and renal effects in experimental heart failure. Eur Heart J (2005) 0.96
Introduction of metoprolol increases plasma B-type cardiac natriuretic peptides in mild, stable heart failure. Circulation (2006) 0.96
Human cerebral arteriovenous vasoactive exchange during alterations in arterial blood gases. J Appl Physiol (1985) (2008) 0.96
Effect of body mass index on diagnostic and prognostic usefulness of amino-terminal pro-brain natriuretic peptide in patients with acute dyspnea. Arch Intern Med (2007) 0.94
Usefulness of intermediate amino-terminal pro-brain natriuretic peptide concentrations for diagnosis and prognosis of acute heart failure. Am J Cardiol (2006) 0.93
Urocortin-1 infusion in normal humans. J Clin Endocrinol Metab (2004) 0.92
The chromosome 9p21.3 coronary heart disease risk allele is associated with altered gene expression in normal heart and vascular tissues. PLoS One (2012) 0.91
Prolonged urocortin 2 administration in experimental heart failure: sustained hemodynamic, endocrine, and renal effects. Hypertension (2011) 0.91
Direct cardiac actions of erythropoietin (EPO): effects on cardiac contractility, BNP secretion and ischaemia/reperfusion injury. Clin Sci (Lond) (2008) 0.91
The effects of medications on circulating levels of cardiac natriuretic peptides. Ann Med (2007) 0.91
Asian Sudden Cardiac Death in Heart Failure (ASIAN-HF) registry. Eur J Heart Fail (2013) 0.91
Characterisation of proghrelin peptides in mammalian tissue and plasma. J Endocrinol (2007) 0.90
Plasma cardiotrophin-1 is elevated in human hypertension and stimulated by ventricular stretch. Cardiovasc Res (2005) 0.90
Angiotensin type-1 receptor A1166C gene polymorphism correlates with oxidative stress levels in human heart failure. Hypertension (2006) 0.90
Prediction of cardiac rhythm 1 year following cardioversion for atrial fibrillation. N Z Med J (2011) 0.90
Betaine and secondary events in an acute coronary syndrome cohort. PLoS One (2012) 0.90
Adrenomedullin expression in rat uterus is correlated with plasma estradiol. Am J Physiol Endocrinol Metab (2002) 0.89
NTproBNP-guided drug treatment for chronic heart failure: design and methods in the "BATTLESCARRED" trial. Eur J Heart Fail (2006) 0.89
Metabolic adaptation to a disruption in oxygen supply during myocardial ischemia and reperfusion is underpinned by temporal and quantitative changes in the cardiac proteome. J Proteome Res (2012) 0.89
Plasma corin levels provide minimal prognostic utility incremental to natriuretic peptides in chronic systolic heart failure. J Card Fail (2010) 0.89
Iron deficiency in a multi-ethnic Asian population with and without heart failure: prevalence, clinical correlates, functional significance and prognosis. Eur J Heart Fail (2014) 0.89
Generation and characterization of a mouse model of the metabolic syndrome: apolipoprotein E and aromatase double knockout mice. Am J Physiol Endocrinol Metab (2011) 0.89
Angiotensinogen M235T and T174M gene polymorphisms in combination doubles the risk of mortality in heart failure. Hypertension (2006) 0.88
Genomic risk variants at 1p13.3, 1q41, and 3q22.3 are associated with subsequent cardiovascular outcomes in healthy controls and in established coronary artery disease. Circ Cardiovasc Genet (2011) 0.87
Comparison of infarct-derived and control ovine cardiac myofibroblasts in culture: response to cytokines and natriuretic peptide receptor expression profiles. Am J Physiol Heart Circ Physiol (2006) 0.87
Influence of natriuretic peptide receptor-1 on survival and cardiac hypertrophy during development. Biochim Biophys Acta (2009) 0.87
Regional clearance of amino-terminal pro-brain natriuretic peptide from human plasma. Eur J Heart Fail (2009) 0.87
Plasma urocortin 1 in human heart failure. Circ Heart Fail (2009) 0.86
Urotensin II immunoreactivity in the human circulation: evidence for widespread tissue release. Clin Chem (2009) 0.86
Amino-terminal proCNP: a putative marker of cartilage activity in postnatal growth. Pediatr Res (2005) 0.86
Monitoring of heart failure: comparison of left atrial pressure with intrathoracic impedance and natriuretic peptide measurements in an experimental model of ovine heart failure. Clin Sci (Lond) (2011) 0.86
Apelin-13 induces a biphasic haemodynamic response and hormonal activation in normal conscious sheep. J Endocrinol (2006) 0.86
Combined endopeptidase inhibition and adrenomedullin in sheep with experimental heart failure. Hypertension (2002) 0.85
Renal and cardiac function for long-term (10 year) risk stratification after myocardial infarction. Eur Heart J (2009) 0.85
B-type natriuretic peptides and echocardiographic measures of cardiac structure and function. JACC Cardiovasc Imaging (2009) 0.84
Comparison of different surgical techniques in 112 consecutive patients with aortic root operations: when should the valve be spared? J Heart Valve Dis (2014) 0.84
OSA and coronary plaque characteristics. Chest (2014) 0.83
Endogenous urocortins reduce vascular tone and renin-aldosterone/endothelin activity in experimental heart failure. Eur Heart J (2005) 0.83
First identification of circulating prepro-A-type natriuretic peptide (preproANP) signal peptide fragments in humans: initial assessment as cardiovascular biomarkers. Clin Chem (2012) 0.83
Coenzyme Q10; an adjunctive therapy for congestive heart failure? N Z Med J (2009) 0.82
Effect of urocortin 1 infusion in humans with stable congestive cardiac failure. Clin Sci (Lond) (2005) 0.82
Plasma amino-terminal pro C-type natriuretic Peptide in the neonate: relation to gestational age and postnatal linear growth. J Clin Endocrinol Metab (2007) 0.82